SG11202005858WA - Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same - Google Patents

Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same

Info

Publication number
SG11202005858WA
SG11202005858WA SG11202005858WA SG11202005858WA SG11202005858WA SG 11202005858W A SG11202005858W A SG 11202005858WA SG 11202005858W A SG11202005858W A SG 11202005858WA SG 11202005858W A SG11202005858W A SG 11202005858WA SG 11202005858W A SG11202005858W A SG 11202005858WA
Authority
SG
Singapore
Prior art keywords
same
ige
receptor
pharmaceutical composition
extracellular domain
Prior art date
Application number
SG11202005858WA
Inventor
Young Chul Sung
Zungyoon Yang
Original Assignee
Gi Innovation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gi Innovation Inc filed Critical Gi Innovation Inc
Publication of SG11202005858WA publication Critical patent/SG11202005858WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Polymers & Plastics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11202005858WA 2018-01-08 2019-01-08 Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same SG11202005858WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20180002248 2018-01-08
PCT/KR2019/000274 WO2019135668A1 (en) 2018-01-08 2019-01-08 Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same

Publications (1)

Publication Number Publication Date
SG11202005858WA true SG11202005858WA (en) 2020-07-29

Family

ID=67143676

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005858WA SG11202005858WA (en) 2018-01-08 2019-01-08 Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same

Country Status (16)

Country Link
US (1) US20210070833A1 (en)
EP (1) EP3738977A4 (en)
JP (2) JP7128291B2 (en)
KR (1) KR102038675B1 (en)
CN (1) CN111587251B (en)
AU (1) AU2019205743B2 (en)
BR (1) BR112020013805A2 (en)
CA (1) CA3086222A1 (en)
CL (1) CL2020001798A1 (en)
IL (1) IL275591B2 (en)
MX (1) MX2020007030A (en)
PE (1) PE20210043A1 (en)
PH (1) PH12020551021A1 (en)
SG (1) SG11202005858WA (en)
TW (1) TWI713971B (en)
WO (1) WO2019135668A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7128291B2 (en) 2018-01-08 2022-08-30 ジーアイ・イノベイション・インコーポレイテッド Extracellular domain of the alpha subunit of the IgE Fc receptor, pharmaceutical compositions containing the same, and methods of making the same
PE20210108A1 (en) * 2018-01-12 2021-01-19 Gi Innovation Inc COMPOSITION THAT INCLUDES PROBIOTICS AND POLYPEPTIDE THAT HAS BINDING AFFINITY FOR IGE AND USE OF THE SAME
MX2022000285A (en) * 2019-07-08 2022-02-03 Gi Innovation Inc Polypeptide dimer with high sialic acid content, comprising extracellular domain of alpha subunit of ige fc receptor, and pharmaceutical composition comprising same.
US20230279124A1 (en) * 2020-07-17 2023-09-07 Gi Innovation, Inc. Fusion protein comprising ige fc receptor alpha subunit extracellular domain and anti-il-4r antibody, and use thereof
KR20220011931A (en) * 2020-07-22 2022-02-03 (주)지아이이노베이션 Fusion protein comprising ige fc receptor and use for treating canine allergic diseases comprising the same
EP4306103A1 (en) 2021-03-09 2024-01-17 GI Innovation, Inc. Formulation of fusion protein including extracellular domain of alpha subunit of ige fc receptor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067334A (en) 1959-03-13 1962-12-04 Garrett Corp Driving and control means for a plurality of alternators
ATE402958T1 (en) * 2000-09-26 2008-08-15 Genentech Inc ANTAGONISTS OF THE IGE RECEPTOR
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
PT1896071E (en) 2005-06-30 2015-07-09 Janssen Biotech Inc Methods and compositions with enhanced therapeutic activity
WO2008028068A2 (en) * 2006-08-30 2008-03-06 Genentech, Inc. NON-HUMAN PRIMATE FCεR1α POLYPEPTIDES
CN101611052A (en) * 2006-12-13 2009-12-23 苏伯利莫尔公司 The Multimeric Fc receptor polypeptides that comprises the Fc structural domain of modification
ES2623925T3 (en) * 2007-05-30 2017-07-12 Postech Academy-Industry- Foundation Immunoglobulin Fusion Proteins
CN105175553B (en) * 2007-05-30 2019-11-22 浦项工科大学校产学协力团 Domain-immunoglobulin fusion proteins
EP2072527A1 (en) * 2007-12-21 2009-06-24 Altonabiotec AG Fusion polypeptides comprising a SHBG dimerization component and uses thereof
ES2742419T3 (en) 2008-09-17 2020-02-14 Xencor Inc New compositions and methods to treat IgE-mediated disorders
US20110256641A1 (en) * 2010-04-19 2011-10-20 Michael Ling Methods and Systems for Detecting Free IgE
KR101825048B1 (en) 2014-12-31 2018-02-05 주식회사 제넥신 Fusion Polypeptide Comprising GLP and Immunoglobulin Hybrid Fc and use thereof
TWI691512B (en) * 2015-02-20 2020-04-21 日商橘生藥品工業股份有限公司 Fc fusion high affinity IgE receptor alpha chain
US10195272B2 (en) * 2015-03-02 2019-02-05 The Nemours Foundation Adoptive t-cell therapy using FcεRI-based chimeric antigen receptors for treating IgE-mediated allergic diseases
CA2986388C (en) * 2015-06-11 2024-02-27 Genexine, Inc. Modified interleukin-7 protein and uses thereof
KR102038672B1 (en) * 2018-01-08 2019-10-30 (주)지아이이노베이션 PHARMACEUTICAL COMPOSITION COMPRISING RECOMBINANT EXTRACELLULAR DOMAIN OF IgE Fc RECEPTOR SUBUNIT ALPHA
JP7128291B2 (en) 2018-01-08 2022-08-30 ジーアイ・イノベイション・インコーポレイテッド Extracellular domain of the alpha subunit of the IgE Fc receptor, pharmaceutical compositions containing the same, and methods of making the same

Also Published As

Publication number Publication date
CL2020001798A1 (en) 2020-11-13
PE20210043A1 (en) 2021-01-08
EP3738977A1 (en) 2020-11-18
MX2020007030A (en) 2020-12-03
WO2019135668A1 (en) 2019-07-11
AU2019205743A1 (en) 2020-06-25
AU2019205743B2 (en) 2023-11-16
KR102038675B1 (en) 2019-10-30
CN111587251A (en) 2020-08-25
IL275591A (en) 2020-08-31
CA3086222A1 (en) 2019-07-11
EP3738977A4 (en) 2021-12-22
JP7128291B2 (en) 2022-08-30
IL275591B2 (en) 2023-06-01
RU2020122056A (en) 2022-02-10
CN111587251B (en) 2024-05-28
JP2022176971A (en) 2022-11-30
TW201932488A (en) 2019-08-16
US20210070833A1 (en) 2021-03-11
JP7488303B2 (en) 2024-05-21
BR112020013805A2 (en) 2020-12-01
PH12020551021A1 (en) 2021-05-31
JP2021509590A (en) 2021-04-01
TWI713971B (en) 2020-12-21
KR20190084885A (en) 2019-07-17

Similar Documents

Publication Publication Date Title
IL275591A (en) Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same
IL275944B (en) 2/interleukin-2 receptor alpha fusion proteins and methods of use
SG11202011883RA (en) Pharmaceutical combination, composition, and combination formulation containing glucokinase activator and ppar receptor activator, and preparation methods and uses thereof
AU2015254922B2 (en) System and method for the creation and use of visually-diverse high-quality dynamic layouts
IL277288A (en) Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
CL2015002123A1 (en) Modulators of spiro-lactam nmda receptors and their uses
EP3313872A4 (en) CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
IL304521A (en) Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use
CL2015001529A1 (en) Compounds derived from indole carboxamide, p2x7 receptor antagonists; Pharmaceutical composition and its use for the prevention or treatment of neurodegenerative and neuroinflammatory diseases, bone and joint diseases, cardiovascular diseases, among others.
EP3227310A4 (en) Heterobifunctional inhibitors of e-selectins and cxcr4 chemokine receptors
EP3600290A4 (en) Novel modulators of the sigma-2 receptor and their method of use
EP3686198A4 (en) mu-OPIOID RECEPTOR AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF IN FIELD OF MEDICINE
EP3576793A4 (en) Compositions and methods for augmenting antibody mediated receptor signaling
EP3603800A4 (en) Catalyst for preparing 1,5-pentanediol via hydrogenolysis of tetrahydrofurfuryl alcohol, method and application thereof
EP3177289A4 (en) Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
PT3495352T (en) Crystal form of androgen receptor antagonist medication, preparation method therefor, and use
EP3541790A4 (en) Novel modulators of the 5-hydroxytryptamine receptor 7 and their method of use
EP3712144A4 (en) P2x3 and/or p2x2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof
EP3524633A4 (en) Novel resin-linear organopolysiloxane block copolymer, use of same, and method for producing same
HK1245794A1 (en) Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal
EP3939609A4 (en) Liquid composition comprising antibody of human interleukin-4 receptor alpha
DK3744316T3 (en) OPHTHALMIC PHARMACEUTICAL COMPOSITION, METHOD OF PREPARATION THEREOF AND USE THEREOF
ZA201701852B (en) Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
WO2014160956A3 (en) Cartilage-binding fusion proteins
EP3349773A4 (en) Methods and compositions for treatment of gaucher disease via modulation of c5a receptor